⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NUVB News
Nuvation Bio Inc.
Nuvation Bio Inc. Announces Full Exercise of Greenshoe Option in $287.5 Million Convertible Senior Notes Offering
prnewswire.com
NUVB
Form 8-K
sec.gov
NUVB
Nuvation Bio Announces Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated in the United Kingdom
prnewswire.com
NUVB
Nuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notes
prnewswire.com
NUVB
Nuvation Bio Announces Proposed Convertible Senior Notes Offering
prnewswire.com
NUVB
Form 8-K
sec.gov
NUVB
Nuvation Bio to Present New Quality-of-Life Data for IBTROZI® (Taletrectinib) in Patients with ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2026 Annual Meeting
prnewswire.com
NUVB
Nuvation Bio to Collaborate with Thermo Fisher Scientific for U.S.-Based Manufacturing of IBTROZI® for ROS1-Positive Non-Small Cell Lung Cancer
prnewswire.com
NUVB
TMO
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Nuvation Bio Inc. (NYSE: NUVB)
prnewswire.com
NUVB
Nuvation Bio Announces FDA Acceptance of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in Advanced ROS1-Positive Non-Small Cell Lung Cancer
prnewswire.com
NUVB